LEXINGTON, Mass.--(BUSINESS WIRE)--June 29, 2006--Predix Pharmaceuticals, which recently announced a definitive agreement to merge with EPIX Pharmaceuticals (NASDAQ:EPIX - News), announced today that preclinical data from studies in obesity and cognitive impairment with PRX-07034, a highly selective, proprietary 5-HT6 receptor antagonist, will be presented at the Serotonin Club Meeting 2006. Predix recently entered PRX-07034 into Phase I clinical development as a small-molecule drug candidate with the potential to treat obesity and also cognitive impairment (associated with Alzheimer's disease or schizophrenia).
